CA2435287A1 - Preparations de liberation d'acide nucleique - Google Patents

Preparations de liberation d'acide nucleique Download PDF

Info

Publication number
CA2435287A1
CA2435287A1 CA002435287A CA2435287A CA2435287A1 CA 2435287 A1 CA2435287 A1 CA 2435287A1 CA 002435287 A CA002435287 A CA 002435287A CA 2435287 A CA2435287 A CA 2435287A CA 2435287 A1 CA2435287 A1 CA 2435287A1
Authority
CA
Canada
Prior art keywords
formulation
nucleic acid
components
reactive
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002435287A
Other languages
English (en)
Inventor
Shikha P. Barman
Krishnendu Roy
Mary Lynne Hedley
Daqing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2435287A1 publication Critical patent/CA2435287A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention est fondée sur la découverte selon laquelle des compositions et des préparations polymériques injectables et compatibles avec de l'acide nucléique peuvent être mises au point structurellement pour réguler in vivo l'activité de l'acide nucléique ou l'expression génique, par exemple, par régulation de la biodisponibilité de l'acide nucléique par modulation de la biodégradabilité et de la densité de réticulation du réseau formé par les constituants de la préparation. Le réseau polymérique encapsule l'acide nucléique, et non seulement régule la libération de l'ADN, mais le protège également de la dégradation. L'invention constitue une amélioration par rapport au modes de libération génique antérieurs, en ce que l'expression génique peut être régulée par modulation d'un réseau polymérique formé par combinaison d'au moins deux constituants solubles dans l'eau pouvant réagir l'un avec l'autre. L'acide nucléique d'intérêt est incorporé dans le réseau pour être libéré de manière constante, en fonction du niveau et de la durée d'activité ou d'expression voulus.
CA002435287A 2001-01-17 2002-01-17 Preparations de liberation d'acide nucleique Abandoned CA2435287A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26221901P 2001-01-17 2001-01-17
US60/262,219 2001-01-17
US27025601P 2001-02-20 2001-02-20
US60/270,256 2001-02-20
US30048401P 2001-06-22 2001-06-22
US60/300,484 2001-06-22
PCT/US2002/001379 WO2002057424A2 (fr) 2001-01-17 2002-01-17 Preparations de liberation d'acide nucleique

Publications (1)

Publication Number Publication Date
CA2435287A1 true CA2435287A1 (fr) 2002-07-25

Family

ID=27401491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002435287A Abandoned CA2435287A1 (fr) 2001-01-17 2002-01-17 Preparations de liberation d'acide nucleique

Country Status (4)

Country Link
EP (1) EP1352072A4 (fr)
JP (1) JP2004521109A (fr)
CA (1) CA2435287A1 (fr)
WO (1) WO2002057424A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
JP2005530695A (ja) * 2002-02-15 2005-10-13 ザイコス インク． 生理活性物質を細胞内に導入するエレクトロポレーション法
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
AU2004286232A1 (en) * 2003-10-23 2005-05-12 Alza Corporation Compositions of stabilized DNA for coating microprojections
CN101137347A (zh) * 2004-11-16 2008-03-05 列日大学 包含水凝胶基质和微载体的活性物质递送系统
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US9393309B2 (en) * 2011-04-19 2016-07-19 Kyoto University Self-gelatinizable nucleic acid
WO2014055493A1 (fr) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Procédés et systèmes s'appliquant à la précipitation de polymères et à la génération de particules
WO2016116922A1 (fr) * 2015-01-19 2016-07-28 Rappaport Family Institute For Research In The Medical Sciences Promotion de la transformation de nf-kappab1 p105 en p50 par l'ubiquitine ligase kpc1, déclenchant un fort effet antitumoral
KR101637883B1 (ko) * 2015-09-30 2016-07-21 선바이오(주) 폴리에틸렌글리콜 수화젤 주사제
KR101666792B1 (ko) 2016-02-05 2016-10-17 주식회사 파마리서치프로덕트 핵산 및 키토산을 포함하는 온도감응성 하이드로겔 조성물
CN111333878B (zh) * 2019-05-23 2020-11-10 吾奇生物医疗科技(镇江)有限公司 一种双交联壳聚糖水凝胶及其制备方法和应用
CN109134855B (zh) * 2018-07-23 2021-03-23 安徽大学 一种酸敏感的聚酰胺胺的阳离子聚合物poeamam及其制备方法和应用
CN113683780B (zh) * 2021-09-15 2022-07-05 广州医科大学 具有穿膜活性和细胞核定位功能的抗血清、低细胞毒性的聚氨基酸类基因递送载体材料
CN116212098B (zh) * 2023-03-14 2024-08-13 四川大学 一种酸性环境快速响应型多肽粘合剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3940316A1 (de) * 1989-12-06 1991-06-13 Bollig & Kemper Waessrige dispersionen von vernetzten polymermikroteilchen
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
EP0920339A2 (fr) * 1996-07-09 1999-06-09 The Johns Hopkins University Systeme d'administration de genes
EP0932390A1 (fr) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
AU744588B2 (en) * 1997-06-30 2002-02-28 Ciba Specialty Chemicals Water Treatments Limited Polymeric materials and their use
DK0987029T3 (da) * 1998-08-28 2003-03-31 Transgene Sa Anvendelse af en kationisk polymer til fremstilling af et kompleks med nukleinsyre samt relaterede præparater

Also Published As

Publication number Publication date
EP1352072A4 (fr) 2004-09-01
JP2004521109A (ja) 2004-07-15
EP1352072A2 (fr) 2003-10-15
WO2002057424A2 (fr) 2002-07-25
WO2002057424A3 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
US20040147466A1 (en) Nucleic acid delivery formulations
Kabanov et al. Pluronic® block copolymers: novel functional molecules for gene therapy
Jeong et al. Molecular design of functional polymers for gene therapy
CA2435287A1 (fr) Preparations de liberation d'acide nucleique
JP4987205B2 (ja) 遺伝子送達用核酸製剤および使用方法
Kabanov et al. Pluronic block copolymers for gene delivery
Park et al. Current status of polymeric gene delivery systems
Li et al. Nonviral gene therapy
US20030138407A1 (en) Therapeutic methods for nucleic acid delivery vehicles
Li et al. Supramolecular anchoring of DNA polyplexes in cyclodextrin-based polypseudorotaxane hydrogels for sustained gene delivery
Sano et al. Atelocollagen for protein and gene delivery
US20010007771A1 (en) Cationic polymers and lipids for the delivery of nucleic acids
Dass et al. Nanoparticle-mediated interleukin-12 cancer gene therapy
Adolph et al. Enhanced performance of plasmid DNA polyplexes stabilized by a combination of core hydrophobicity and surface PEGylation
JP5294858B2 (ja) 生理活性ポリペプチドまたはタンパク質内包高分子ポリマーミセルおよびその製造方法
Kushibiki et al. A new gene delivery system based on controlled release technology
Meyer et al. A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
AU2003219805B2 (en) Electroporation methods for introducing bioactive agents into cells
US20050118718A1 (en) Stabilization and controlled delivery of ionic biopharmaceuticals
Lei et al. Dual-RNA controlled delivery system inhibited tumor growth by apoptosis induction and TME activation
AU2002245279A1 (en) Nucleic acid delivery formulations
Leong Polymeric controlled nucleic acid delivery
Huang et al. Recent progress in polymer-based gene delivery vectors
Israel et al. Polymers in gene therapy: antisense delivery systems
Mumper et al. Polymeric gene delivery systems for in vivo gene therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued